Core Pipeline
Bio Health Care
Overview
We provide gene-based therapeutic services for refractory diseases using newly developed microorganisms. Specifically, we prioritize services for Crohn's disease, and concurrently present academic papers to highlight the uniqueness and excellence of this service.
Development Stage
Through repeated clinical trials, the strong therapeutic efficacy of Green Red Bio Metabolome was confirmed. Among them, for the intractable digestive disease Crohn's disease, not only was a strong therapeutic effect observed, but it was also confirmed that there was no relapse after a 5-year follow-up.
Commercialization Plan
Analysis
Once investment is secured, we plan to start the 12-week treatment service through our partner resorts, medical tourism service providers, and global networks. The target for service acquisition is 20,000 people annually, with service fees ranging from USD 150,000 to USD 300,000 per person.
Market Potential and Competitive Advantage
The treatment method we offer is the only one that can guarantee conditions such as "non-surgical", "without aftereffects", "complete recovery", and "no recurrence" as desired by those seeking the service. Moreover, Crohn's disease is known as an incurable, chronic condition, and the treatment costs are enormous.
This therapy is completed over a short, 12-week period, and its total cost remains below one-quarter of what an insured patient would pay in the long run under conventional treatment methods.
Starting with Crohn's disease, we plan to gradually expand the service to other diseases, focusing on intractable diseases to integrate with the existing healthcare industry.
Annual service target:
Direction
20,000 people
(5,000 per quarter)
Revenue target:
6.2 trillion KRW/year
(estimated operating profit margin 26%)